AQST - חוב כולל להון Aquestive Corp

Aquestive Therapeutics (AQST) is implementing breakthrough PharmFilm technologies while awaiting FDA approval for oral adrenaline. The company's debt-to-equity ratio visualizes its financial stability, where the value 0.00 indicates the current level of leverage. Patents for thin films ensure high product margins, while the environmental strategy focuses on minimizing production plastic and the sustainable use of resources.

The growth dynamics of Aquestive Therapeutics (AQST) are clearly reflected through the organization's total debt-to-equity ratio on the GURU.Markets platform. This metric measures the business's reliance on borrowed funds relative to its own equity. The calculation is based on the ratio of all liabilities to net asset value, identifying the risk of excessive credit leverage. For Aquestive Therapeutics (AQST), this balance is critical when implementing soluble film technology. Debt optimization ensures the financial stability necessary to protect the margins of innovative products.